These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3856968)

  • 1. [Various induction therapies in older patients with acute myeloid leukemias].
    Lutz D
    Wien Klin Wochenschr; 1985 Feb; 97(3):137-40. PubMed ID: 3856968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
    Beck JD
    Monatsschr Kinderheilkd; 1986 Aug; 134(8):547-9. PubMed ID: 3464845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia.
    Neri A; Comis M; Brugiatelli M; Martino B; Ronco F
    Haematologica; 1989; 74(1):113-4. PubMed ID: 2498174
    [No Abstract]   [Full Text] [Related]  

  • 5. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
    Saito K
    Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
    Saito K; Furusawa S; Yamada K; Waga K; Aoyagi A; Koike T; Arimura H; Noguchi M; Yamato H; Sakuma H
    Rinsho Ketsueki; 1995 Mar; 36(3):165-74. PubMed ID: 7540220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
    Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
    Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
    Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
    Tsurumi H; Miura T; Yamada T; Sawada M; Nakamura N; Tomoda T; Takahashi T; Oyama M; Moriwaki H; Muto Y
    Rinsho Ketsueki; 1995 Jul; 36(7):657-64. PubMed ID: 7563593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
    Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.